Geron (NASDAQ:GERN)‘s stock had its “buy” rating reissued by equities research analysts at Piper Jaffray Companies in a research report issued on Monday. They presently have a $7.00 price objective on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price target suggests a potential upside of 68.27% from the stock’s current price.
GERN has been the topic of several other reports. BidaskClub raised shares of Geron from a “sell” rating to a “hold” rating in a report on Wednesday, January 24th. Zacks Investment Research lowered shares of Geron from a “buy” rating to a “hold” rating in a report on Tuesday, January 2nd. Stifel Nicolaus set a $4.00 price target on shares of Geron and gave the stock a “hold” rating in a report on Sunday. Finally, ValuEngine raised shares of Geron from a “sell” rating to a “hold” rating in a report on Wednesday, March 14th. Four investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $4.50.
Shares of Geron stock traded down $0.18 during mid-day trading on Monday, reaching $4.16. 5,435,623 shares of the company traded hands, compared to its average volume of 3,363,336. The stock has a market capitalization of $541.40, a price-to-earnings ratio of -23.14 and a beta of 2.77. Geron has a 12 month low of $1.74 and a 12 month high of $4.47.
Geron (NASDAQ:GERN) last issued its quarterly earnings data on Friday, March 16th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by ($0.01). The business had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.41 million. Geron had a negative net margin of 2,621.22% and a negative return on equity of 24.74%. The business’s quarterly revenue was up 103.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.05) earnings per share. equities research analysts forecast that Geron will post -0.02 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GERN. Creative Planning grew its holdings in shares of Geron by 69.8% during the fourth quarter. Creative Planning now owns 308,523 shares of the biopharmaceutical company’s stock valued at $555,000 after buying an additional 126,810 shares during the last quarter. Virtus Fund Advisers LLC purchased a new stake in shares of Geron during the fourth quarter valued at $314,000. Russell Investments Group Ltd. grew its holdings in shares of Geron by 783.9% during the third quarter. Russell Investments Group Ltd. now owns 363,990 shares of the biopharmaceutical company’s stock valued at $794,000 after buying an additional 322,810 shares during the last quarter. State Street Corp grew its holdings in shares of Geron by 9.8% during the second quarter. State Street Corp now owns 5,127,578 shares of the biopharmaceutical company’s stock valued at $14,205,000 after buying an additional 459,700 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. grew its holdings in shares of Geron by 42.0% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 82,426 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 24,370 shares during the last quarter. 37.22% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Geron (GERN) Receives “Buy” Rating from Piper Jaffray Companies” was originally published by Stock Observer and is the property of of Stock Observer. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.thestockobserver.com/2018/03/19/piper-jaffray-companies-reiterates-overweight-rating-for-geron-gern.html.
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.